153 related articles for article (PubMed ID: 16807314)
21. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
[TBL] [Abstract][Full Text] [Related]
22. Identification and quantification of differentially methylated loci by the pyrosequencing technology.
Dejeux E; El abdalaoui H; Gut IG; Tost J
Methods Mol Biol; 2009; 507():189-205. PubMed ID: 18987816
[TBL] [Abstract][Full Text] [Related]
23. Influence of methylated p15 and p16 genes on clinicopathological features in colorectal cancer.
Ishiguro A; Takahata T; Saito M; Yoshiya G; Tamura Y; Sasaki M; Munakata A
J Gastroenterol Hepatol; 2006 Aug; 21(8):1334-9. PubMed ID: 16872319
[TBL] [Abstract][Full Text] [Related]
24. A novel method for sensitive and specific detection of DNA methylation biomarkers based on DNA restriction during PCR cycling.
Kneip C; Schmidt B; Fleischhacker M; Seegebarth A; Lewin J; Flemming N; Seemann S; Schlegel T; Witt C; Liebenberg V; Dietrich D
Biotechniques; 2009 Sep; 47(3):737-44. PubMed ID: 19852759
[TBL] [Abstract][Full Text] [Related]
25. Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens.
Zon G; Barker MA; Kaur P; Groshen S; Jones LW; Imam SA; Boyd VL
Anal Biochem; 2009 Sep; 392(2):117-25. PubMed ID: 19505431
[TBL] [Abstract][Full Text] [Related]
26. Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome.
Draht MX; Smits KM; Jooste V; Tournier B; Vervoort M; Ramaekers C; Chapusot C; Weijenberg MP; van Engeland M; Melotte V
Clin Epigenetics; 2016; 8():44. PubMed ID: 27118999
[TBL] [Abstract][Full Text] [Related]
27. Cloning of the hamster p16 gene 5' upstream region and its aberrant methylation patterns in pancreatic cancer.
Hanaoka M; Shimizu K; Shigemura M; Kato A; Fujii H; Honoki K; Tsujiuchi T
Biochem Biophys Res Commun; 2005 Aug; 333(4):1249-53. PubMed ID: 15979573
[TBL] [Abstract][Full Text] [Related]
28. p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.
Wakabayashi T; Natsume A; Hatano H; Fujii M; Shimato S; Ito M; Ohno M; Ito S; Ogura M; Yoshida J
Neurosurgery; 2009 Mar; 64(3):455-61; discussion 461-2. PubMed ID: 19240607
[TBL] [Abstract][Full Text] [Related]
29. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3.
Tan SH; Ida H; Lau QC; Goh BC; Chieng WS; Loh M; Ito Y
Oncol Rep; 2007 Nov; 18(5):1225-30. PubMed ID: 17914577
[TBL] [Abstract][Full Text] [Related]
30. DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer.
Viet CT; Jordan RC; Schmidt BL
J Calif Dent Assoc; 2007 Dec; 35(12):844-9. PubMed ID: 18240747
[TBL] [Abstract][Full Text] [Related]
31. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
[TBL] [Abstract][Full Text] [Related]
32. Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.
Chim CS; Wong KY; Loong F; Lam WW; Srivastava G
Hum Pathol; 2007 Dec; 38(12):1849-57. PubMed ID: 17900658
[TBL] [Abstract][Full Text] [Related]
33. Methylation-specific PCR.
Licchesi JD; Herman JG
Methods Mol Biol; 2009; 507():305-23. PubMed ID: 18987823
[TBL] [Abstract][Full Text] [Related]
34. [Chronic hepatitis B virus infection and the methylation status of p16INK4A promoter].
Zhu R; Li BZ; Ling YQ; Zhang HP; Li H; Liu Y; Hu XQ; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):166-70. PubMed ID: 17649629
[TBL] [Abstract][Full Text] [Related]
35. A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis.
Hattermann K; Mehdorn HM; Mentlein R; Schultka S; Held-Feindt J
Anal Biochem; 2008 Jun; 377(1):62-71. PubMed ID: 18384736
[TBL] [Abstract][Full Text] [Related]
36. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer.
Ikoma H; Ichikawa D; Daito I; Nobuyuki T; Koike H; Okamoto K; Ochiai T; Ueda Y; Yamagishi H; Otsuji E
Hepatogastroenterology; 2007; 54(75):946-50. PubMed ID: 17591100
[TBL] [Abstract][Full Text] [Related]
37. The role of pyrosequencing in head and neck cancer epigenetics: correlation of quantitative methylation data with gene expression.
Shaw RJ; Hall GL; Lowe D; Liloglou T; Field JK; Sloan P; Risk JM
Arch Otolaryngol Head Neck Surg; 2008 Mar; 134(3):251-6. PubMed ID: 18347248
[TBL] [Abstract][Full Text] [Related]
38. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
[TBL] [Abstract][Full Text] [Related]
39. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease.
Model F; Osborn N; Ahlquist D; Gruetzmann R; Molnar B; Sipos F; Galamb O; Pilarsky C; Saeger HD; Tulassay Z; Hale K; Mooney S; Lograsso J; Adorjan P; Lesche R; Dessauer A; Kleiber J; Porstmann B; Sledziewski A; Lofton-Day C
Mol Cancer Res; 2007 Feb; 5(2):153-63. PubMed ID: 17314273
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways.
Murao K; Kubo Y; Ohtani N; Hara E; Arase S
Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
